{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104151","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.737507+00:00","generated_at":"2026-05-17T19:39:03.850769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioAge Labs Q2 net loss $21.6M, cash $313.4M; BGE-102 Phase 1 on track for 2H 2025","bullets":["Net loss $21.6M ($0.60/share) vs $13.6M loss in Q2 2024; R&D expenses rose to $19.8M.","Cash and marketable securities $313.4M as of June 30, 2025; runway through 2029.","BGE-102 IND-enabling completed; Phase 1 SAD/MAD starts 2H 2025 with data by year-end.","Option agreement for APJ agonist nanobody with >10x apelin potency; oral APJ patent filed.","Launched HUNT Biobank collaboration to profile 17,000+ samples for aging biology."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104151","json":"https://secwatch.observer/filing/0000950170-25-104151.json","markdown":"https://secwatch.observer/filing/0000950170-25-104151.md","text":"https://secwatch.observer/filing/0000950170-25-104151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000095017025104151/0000950170-25-104151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000095017025104151/bioa-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:39:03.850769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}